Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30458187 | 0.86 | DGAT1 (0.35) | DGAT1MTNR1AMTNR1BPDE10ADUT | |
| SCHEMBL21178188 | 0.81 | DGAT1 (0.46) | DGAT1MTNR1AMTNR1BPDE10ANPC1 | |
| SCHEMBL29513954 | 0.81 | DGAT1 (0.36) | DGAT1MTNR1AMTNR1BPDE10ANPC1 | |
| SCHEMBL20455636 | 0.81 | DGAT1 (0.36) | DGAT1MTNR1AMTNR1BPDE10ANPC1 | |
| SCHEMBL21184585 | 0.80 | DGAT1 (0.34) | DGAT1MTNR1AMTNR1BNPC1 | |
| SCHEMBL21178221 | 0.80 | DGAT1 (0.34) | DGAT1MTNR1AMTNR1BNPC1 | |
| SCHEMBL30940042 | 0.79 | KLKB1 (0.39) | DGAT1MTNR1AMTNR1BNPC1DUT | |
| SCHEMBL30850120 | 0.79 | MTNR1A (0.40) | DGAT1MTNR1AMTNR1BNPC1DUT | |
| SCHEMBL31497514 | 0.77 | MTNR1A (0.41) | DGAT1MTNR1AMTNR1BNPC1KLKB1 | |
| SCHEMBL20553711 | 0.77 | DGAT1 (0.37) | DGAT1MTNR1AMTNR1BNPC1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| EP-4408845-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023052783-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | DGAT1 840/4885CCR1 17/4885MTNR1A 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.